| [1] |
Kitahara CM, Sosa JA. The changing incidence of thyroid cancer[J]. Nat Rev Endocrinol, 2016, 12(11):646-653．
|
| [2] |
McNeil C. Annual cancer statistics report raises key questions[J]. J Natl Cancer Inst, 2006, 98(22):1598-1599.
|
| [3] |
张超杰. 导言:分化型甲状腺癌治疗的争论与进展[J]. 医学与哲学, 2012, 33(10B):8.
|
| [4] |
应则贵. 甲状腺癌的外科手术治疗研究进展[J]. 中国乡村医药, 2014, 21(8):96-98.
|
| [5] |
Gambardella C, Tartaglia E, Nunziata A, et al. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients[J]. World J Surg Oncol, 2016, 14(1):247．
|
| [6] |
Hennessy M, Goldenberg D. The role of prophylactic central neck dissection in the treatment of differentiated thyroid cancer[J]. Rambam Maimonides Med J, 2016, 7(1):e0007．
|
| [7] |
Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes[J]. Langenbecks Arch Surg, 2007, 392(4):417-422.
|
| [8] |
Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid[J]. World J Surg, 2004, 28(5):498-501.
|
| [9] |
浮姣，侯鹏，施秉银. 甲状腺癌治疗进展[J]. 药品评价, 2012, 9(13):6-12+18.
|
| [10] |
Conzo G, Tartaglia E, Avenia N, et al. Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends[J]. World J Surg Oncol, 2016, 14:149．
|
| [11] |
孙广伟，王本锋. 内镜手术治疗甲状腺癌应用进展[J]. 西部医学, 2013, 25(1):156-157.
|
| [12] |
Paek SH, Kang KH. Robotic thyroidectomy and cervical neck dissection for thyroid cancer[J]. Gland Surg, 2016, 5(3):342-351．
|
| [13] |
缪英杰，夏飞. 甲状腺癌诊断与治疗研究新进展[J]. 中国临床研究, 2014, 27(3):356-358.
|
| [14] |
Shi RL, Liao T, Qu N, et al. The usefulness of preoperative thyroid-stimulating hormone for predicting differentiated thyroid microcarcinoma[J]. Otolaryngol Head Neck Surg, 2016, 154(2):256-262.
|
| [15] |
李芳，李秀钧. 甲状腺癌药物治疗进展[J]. 药品评价, 2013, 10(15):35-41.
|
| [16] |
Gershengorn MC, Neumann S. Update in TSH receptor agonists and antagonists[J]. J Clin Endocrinol Metab, 2012, 97(12):4287-4292.
|
| [17] |
于颖娟. 甲状腺癌的诊断与治疗进展[J]. 中国现代医生, 2012, 50(18):18-19.
|
| [18] |
Machac J. Thyroid cancer in pediatrics[J]. Endocrinol Metab Clin North Am, 2016, 45(2):359-404．
|
| [19] |
胡莹莹，蒋宁一. 131I治疗分化型甲状腺癌的现状和进展[J]. 国际放射医学核医学杂志, 2006, 30(6):343-346.
|
| [20] |
陈立波. 钠/碘同向转运体与放射性碘治疗[J]. 国外医学(放射医学核医学分册), 2001, 205(6):258-261.
|
| [21] |
Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets[J]. Mod Pathol, 2008, 21(Suppl 2):S37-43.
|
| [22] |
Hegazi M, Azadi A, Jain D, et al. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer[J]. Drugs Today (Barc), 2015, 51(12):689-694.
|
| [23] |
冀叶，马静，李晓江. 甲状腺癌的分子靶向治疗进展[J]. 肿瘤, 2011, 31(7):671-674.
|
| [24] |
Bulotta S, Celano M, Costante G, et al. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine[J]. Endocrine, 2016, 52(2):214-221.
|
| [25] |
Costa R, Carneiro BA, Chandra S, et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives[J]. Drug Des Devel Ther, 2016, 10:873-884.
|
| [26] |
Jean GW, Mani RM, Jaffry A, et al. Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers[J]. JAMA Oncol, 2016, 2(4):529-534.
|
| [27] |
Kwon J, Wu HG, Youn YK, et al. Role of adjuvant postoperative external beam radiotherapy for well differentiated thyroid cancer[J]. Radiat Oncol J, 2013, 3(13):162-170．
|
| [28] |
吴长华，韩大力，王亮, 等. 精确放疗治疗甲状腺癌的研究进展[J]. 临床肿瘤学杂志, 2016, 22(7):665-668.
|
| [29] |
Kiess AP, Agrawal N, Brierley JD, et al.External-beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American Head and Neck Society[J]. Head Neck, 2016, 38(4):493-498．
|
| [30] |
Sun XS, Sun SR, Guevara N, et al．Indications of external beam radiation therapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques[J]. Crit Rev Oncol Hematol, 2013, 86(1):52-68．
|
| [31] |
张九成，任庆荣，廖玲霞, 等. 调强放疗甲状腺癌术后残留的疗效分析[J]. 实用癌症杂志, 2014, 29(6):648-650.
|
| [32] |
苏东玮，盛湲. 甲状腺癌生物治疗的研究进展[J]. 中国医药指南, 2011, 9(34):293-295.
|
| [33] |
刘宇，赵晓珍. 甲状腺癌的中医证型和用药规律分析[J]. 山西中医学院学报, 2015, 16(5):8-10.
|
| [34] |
王斌，林兰，倪青, 等. 中医辅助西医治疗甲状腺癌优势探究[J]. 北京中医药, 2011, 30(5):354-355.
|